No Data
Jacobson Pharma (02633.HK)'s half-year continuous operation business profit is expected to increase by more than 40% annually in the "Yingxi".
jacobson pharma (02633.HK) announced a joyful profit, expecting that by the end of September this year, the semi-annual profit from its ongoing business operations will increase by over 40% compared to the same period last year. This is mainly attributed to the stable performance of the non-patented pharmaceutical business in the public and private sectors, as well as the revenue contribution from newly authorized products and strong launches of new products. The leverage enhancement of production facilities and effective cost control measures have also driven the related growth. The company stated that after distributing JBM Healthcare (02161.HK) shares as a special stock dividend, the company will no longer include the performance of JBM Healthcare and its subsidiaries in its accounts, expecting that the equity holders of the company will hold the equity
jbm healthcare (02161.HK) plans to hold a board of directors meeting on November 19 to approve mid-term performance.
Granolink 4th November | jbm healthcare (02161.HK) announced that the board of directors notified that the board meeting will be held on 19th November 2024 (Tuesday), to consider and approve the mid-term performance of the company and its subsidiaries for the six months ending 30th September 2024 for publication, and to consider recommending the distribution of interim dividends (if any), as well as handling other matters.
JBM HEALTHCARE: Date of Board Meeting
JBM (Healthcare) Expects at Least 50% Higher H1 Profit
Hong Kong stocks surge | jbm healthcare soared nearly 23%, expecting a more than 50% increase in mid-term profit
Great Wall Securities, November 1st - jbm healthcare (2161.HK) surged today, rising by 22.92% at one point to HK$1.18, with a trading volume exceeding 11 million Hong Kong dollars, and a latest market cap exceeding 0.9 billion Hong Kong dollars. The group announced that the shareholder's attributable profit for the mid-year ending September increased by not less than 50% year-on-year. The company's shareholder's attributable profit for the mid-year of 2023 is 62.461 million Hong Kong dollars. The company stated that the increase in profit was mainly attributed to the strong sales momentum of the group's core brands, especially the Hejigong in the brand medicine division and the Baoji Pill in the brand traditional chinese medicine division. In addition, the concentrated traditional chinese medicine granule business continues.
JBM Healthcare (02161) announced a profit and expects the attributable comprehensive profit of shareholders to increase by no less than 50% in the mid-term.
JBM Healthcare (02161) announced that the Group expects the shareholders' share of the six months ended September 30, 2024...
No Data
No Data